Unlike traditional chemotherapy, which offers limited benefits in advanced ESCC, PD-1 inhibitors—with or without chemotherapy—have shown improved outcomes in phase 3 trials and are now recommended in international guidelines (9–11). This evidence concerns the gene PDCD1 and esophageal squamous cell carcinoma.